Chronic Lymphocytic Leukemia

Long-term Data: Acalabrutinib Provides Tolerable, Durable Responses in Relapsed/Refractory CLL

May 18, 2020

Long-term data from a phase Ib/II trial of the BTK inhibitor acalabrutinib were recently published. Acalabrutinib appears to evoke durable responses with good safety and efficacy.

Tumor Mutational Load Can Help Fine-Tune Prognoses in CLL

May 18, 2020

Patients with chronic lymphocytic leukemia face uncertain futures, as clinicians can have a difficult time predicting whether and when a patient will need treatment. New research suggests tumor mutational load could be a helpful prognostic tool.

Acalabrutinib May Be A Safer Alternative to Ibrutinib in CLL

May 07, 2020

In an interview with Targeted Oncology, Lori A. Leslie, MD, discussed the importance of analyzing treatment outcomes in real-world patients with chronic lymphocytic leukemia compared with only reviewing data from clinical trials that do not represent all patients seen in the community setting.

Comparing Toxicity Profiles of Available Frontline Agents in CLL

May 05, 2020

Jennifer Woyach, MD, discusses the adverse events that differentiate the toxicity profiles of the treatments that are available in the frontline setting for patients with chronic lymphocytic leukemia.

U2 Regimen Improves PFS in Previously Treated and Relapsed/Refractory CLL Cohorts

May 05, 2020

"It’s extremely gratifying to see positive results for this important trial exploring the combination of umbralisib and ublituximab in patients with both front-line and relapsed/refractory CLL."

Follow-Up Shows Venetoclax Plus Rituximab has Long-Term Efficacy in CLL

April 28, 2020

Alexey V. Danilov, MD, PhD, discusses a treatment regimen of venetoclax plus rituximab used for patients with chronic lymphocytic leukemia the 2019 American Society of Hematology Annual Meeting.

Longest Follow-Up Maintains Ibrutinib Benefit in CLL/SLL Across Treatment Settings

April 13, 2020

The longest follow-up for ibrutinib monotherapy to date maintained the benefit of the Bruton’s tyrosine kinase inhibitor for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma across settings.

Prognostic Tool Predicts Length of Watch and Wait Period in CLL

April 10, 2020

The appropriate gap between diagnosis of chronic lymphocytic leukemia and treatment is now clearer as a new prognostic tool, IPS-E, that can predict the length of “watch and wait” has been introduced, according to a press release from the American Society of Hematology.

Early FCR Lacks Evidence to Change Standard Watch & Wait in Stage Binet A High-Risk CLL

April 02, 2020

Although fludarabine, cyclophosphamide, and rituximab may be efficient in inducing remission for the treatment of patients with Binet A high-risk chronic lymphocytic leukemia, recent data published in Leukemia suggest there is no evidence that this would be better than the current standard of care, which is the “watch and wait” approach.